{{Short description|Swiss pharmaceutical company}} '''Novimmune''' is a privately held Swiss pharmaceutical development company focusing on monoclonal antibody therapies for treatment of immune-related diseases.<ref>{{cite web|url=http://www.fiercebiotech.com/biotech/novimmune-s-ni-0501-granted-breakthrough-therapy-designation-by-us-fda-for-treatment-of|title=Novimmune's NI-0501 Granted Breakthrough Therapy Designation by US FDA for Treatment of Patients With Primary Hemophagocytic Lymphohistiocytosis (HLH) - FierceBiotech|website=www.fiercebiotech.com}}</ref> The company was founded in 1998.<ref>{{cite web|url=https://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapId=140159|title=Novimmune SA: Private Company Information - Bloomberg|website=www.bloomberg.com}}</ref>
Novimmune has six publicly disclosed drug in their pipeline: * NI-0101, an anti-TLR4 antibody being developed in partnership with Genentech. A phase I clinical trial was completed in 2014<ref>{{cite web|url=https://www.clinicaltrials.gov/ct2/show/NCT01808469|title=First in Human Study of an Anti-Toll-like Receptor 4 (TLR4) Monoclonal Antibody (NI-0101) in Adult Healthy Volunteers - Full Text View - ClinicalTrials.gov|publisher=}}</ref> and phase II trials are expected to begin in early 2017.<ref>{{cite web|url=https://www.novimmune.com/en/pipeline/ni-0101-anti-tlr4.html|title=Pipeline - NI-0101 anti-TLR4|website=www.novimmune.com}}</ref> * NI-0401, an anti-CD3ε antibody being developed in partnership with Tiziana Life Sciences. Phase II trials in patients with Crohn's disease and transplant rejection finished in 2008 and 2009, respectively.<ref>{{cite web|url=https://www.clinicaltrials.gov/ct2/show/NCT00805909|title=NI-0401 in Patients With Acute Renal Allograft Rejection - Full Text View - ClinicalTrials.gov|publisher=}}</ref> * NI-0501, an anti-IFNγ antibody, is in development for hemophagocytic lymphohistiocytosis.<ref>{{Cite web |url=https://www.novimmune.com/en/pipeline/ni-0501-anti-ifngamma.html |title=Pipeline | NI-0501 anti-IFNγ |access-date=2017-01-11 |archive-url=https://web.archive.org/web/20170113153746/https://www.novimmune.com/en/pipeline/ni-0501-anti-ifngamma.html |archive-date=2017-01-13 |url-status=dead }}</ref><ref>{{cite web|url=https://www.clinicaltrials.gov/ct2/show/NCT02069899|title=Long-term Follow-up of HLH Patients Who Received Treatment With NI-0501, an Anti-interferon Gamma Monoclonal Antibody - Full Text View - ClinicalTrials.gov|publisher=}}</ref> A phase II/III trial began in 2013 and is ongoing.<ref>{{cite web|url=https://www.clinicaltrials.gov/ct2/show/NCT01818492|title=A Study to Investigate the Safety and Efficacy of an Anti-IFNγ mAb in Children Affected by Primary Haemophagocytic Lymphohistiocytosis - Full Text View - ClinicalTrials.gov|publisher=}}</ref> The FDA awarded breakthrough status to the drug in 2016.<ref>{{cite web|url=http://adisinsight.springer.com/drugs/800035226|title=Emapalumab - NovImmune - AdisInsight|website=adisinsight.springer.com}}</ref> * NI-1401, an anti-IL17 drug being developed in partnership with Genentech for inflammatory and auto-immune diseases.<ref>{{cite web|url=https://www.novimmune.com/en/pipeline/ni-1401-anti-il17.html|title=Pipeline - NI-1401 anti-IL17|website=www.novimmune.com}}</ref> * NI-1701, an anti-CD47, anti-CD19 bispecific antibody in development for treatment of B-cell hematological cancers. * NI-1801, an anti-CD47, anti-mesothelin bispecific antibody in the preclinical phase of development for treatment of solid tumors.<ref>{{cite web|url=https://www.novimmune.com/en/pipeline/ni-1801-anti-cd47mesothelin.html|title=Pipeline - NI-1801 anti-CD47/Mesothelin|website=www.novimmune.com}}</ref> No drugs have been approved yet.
== References == {{reflist}}
Category:Pharmaceutical companies of Switzerland